BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Journal: Nature Medicine

Published: 2020-05-25

DOI: 10.1038/s41591-020-0880-x

Affiliations: 27

Authors: 26

Go to article
Institutions Share
BioLineRx Ltd., Israel 0.19
Division of Oncology, WUSTL, United States of America (USA) 0.04
University Hospital of Fuenlabrada, Spain 0.04
Department of Obstetrics and Gynecology, Ochsner Health System, United States of America (USA) 0.04
Samsung Medical Center (SMC), South Korea 0.04
Harvard Medical School (HMS), United States of America (USA) 0.04
Mayo Clinic Comprehensive Cancer Center, United States of America (USA) 0.04
Goldyne-Savad Institute of Gene Therapy, HUJI, Israel 0.04
Merck & Co., Inc., United States of America (USA) 0.04
Investigación Sanitaria del Hospital Gregorio Marañón (IISGM), Spain 0.04
Sackler Faculty of Medicine, TAU, Israel 0.04
StatExcellence Ltd., Israel 0.04
The Translational Genomics Research Institute (TGen), United States of America (USA) 0.04
HonorHealth Research Institute, United States of America (USA) 0.04
Vall d'Hebron University Hospital (HUVH), ICS, Spain 0.04
Rambam Health Care Campus (RambamHCC), IIT, Israel 0.04
Center for Applied Medical Research (CIMA), UNAV, Spain 0.04
Joan and Sanford I. Weill Department of Medicine, Cornell University, United States of America (USA) 0.02
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA) 0.02
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain 0.02
Hospital La Paz Institute for Health Research (IdiPAZ), Spain 0.02
Tel Aviv University (TAU), Israel 0.02
Tel Aviv Sourasky Medical Center, Israel 0.02
Chaim Sheba Medical Center at Tel HaShomer, Israel 0.02
Rabin Medical Center (RMC), TAU, Israel 0.02
Department of Medical Oncology, DFCI, United States of America (USA) 0.02
New York-Presbyterian Hospital, United States of America (USA) 0.02

Return